Immunogen (Immunogen) Cash Flow from Financing : $495.8 Mil (TTM As of Sep. 2023)

View and export this data going back to 1989. Start your Free Trial

What is Immunogen Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Sep. 2023, Immunogen paid $0.0 Mil more to buy back shares than it received from issuing new shares. It received $0.0 Mil from issuing more debt. It paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.0 Mil from paying cash dividends to shareholders. It received $0.0 Mil on other financial activities. In all, Immunogen spent $0.0 Mil on financial activities for the three months ended in Sep. 2023.

Immunogen Cash Flow from Financing Historical Data

The historical data trend for Immunogen's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunogen Cash Flow from Financing Chart

Immunogen Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash Flow from Financing

Get a 7-Day Free Trial

166.81

2.87

195.74

355.74

27.55

Immunogen Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash Flow from Financing	Get a 7-Day Free Trial															0.45	26.07	0.04	437.56	32.13

Immunogen Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Immunogen's Cash from Financing for the fiscal year that ended in Dec. 2022 is calculated as:

	Cash Flow from Financing		(A: Dec. 2022 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	25.649	+	0	+	0	+	0	+	0	+	1.905
=	27.6

Immunogen's Cash from Financing for the quarter that ended in Sep. 2023 is:

	Cash Flow from Financing		(Q: Sep. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0	+	0	+	0	+	0
=	0.0

Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $495.8 Mil.

Immunogen (NAS:IMGN) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Immunogen's issuance of stock for the three months ended in Sep. 2023 was $0.0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Immunogen's repurchase of stock for the three months ended in Sep. 2023 was $0.0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Immunogen's net issuance of debt for the three months ended in Sep. 2023 was $0.0 Mil. Immunogen received $0.0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Immunogen's net issuance of preferred for the three months ended in Sep. 2023 was $0.0 Mil. Immunogen paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Immunogen's cash flow for dividends for the three months ended in Sep. 2023 was $0.0 Mil. Immunogen received $0.0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Immunogen's other financing for the three months ended in Sep. 2023 was $0.0 Mil. Immunogen received $0.0 Mil on other financial activities.

Immunogen Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Immunogen's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunogen (Immunogen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunogen Inc (NAS:IMGN) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

IMGN:Mexico IMU:Germany

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.immunogen.com

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.

Executives

Theresa Wingrove	officer: VP of Regulatory Affairs	IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Renee Lentini	officer: V.P.-Fin., Prin. Acctg. Off.	830 WINTER STREET, WALTHAM MA 02451
Stacy Ann Coen	officer: Chief Business Officer	11 RUSH POND RD, LAKEVILLE MA 02347
Kristine Peterson	director	AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Lauren White	officer: SVP, CFO and PFO	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Mark J Enyedy	director, officer: Chief Executive Officer	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Isabel Kalofonos	officer: SVP & CHIEF COMMERCIAL OFFICER	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Michael Vasconcelles	officer: EVP R&D & MEDICAL AFFAIRS	C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140
Daniel Char	officer: SVP & CHIEF LEGAL OFFICER	C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Kristen Harrington-smith	officer: SVP & Chief Commercial Officer	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Tracey L Mccain	director	C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Helen M. Thackray	director	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
David G Foster	officer: V.P.-Fin., Prin. Acctg. Off.	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Susan Altschuller	officer: SVP and CFO	45 TENNYSON ST., SOMERVILLE MA 02145
Craig Barrows	officer: Vice-President,General Counsel	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451